Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Amphastar Pharmaceuticals (AMPH) Short-Term Debt repayments (2021 - 2023)

Amphastar Pharmaceuticals has reported Short-Term Debt repayments over the past 4 years, most recently at $125.0 million for Q2 2023.

For Q2 2023, Short-Term Debt repayments changed N/A year-over-year to $125.0 million; the TTM value through Jun 2023 reached $125.4 million, changed N/A, while the annual FY2021 figure was $1.2 million, N/A changed from the prior year.
Short-Term Debt repayments for Q2 2023 was $125.0 million at Amphastar Pharmaceuticals, up from $387000.0 in the prior quarter.
Over five years, Short-Term Debt repayments peaked at $125.0 million in Q2 2023 and troughed at $387000.0 in Q3 2021.